These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28655306)

  • 21. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
    Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
    AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
    Castelnuovo B; Mubiru F; Kiragga AN; Musomba R; Mbabazi O; Gonza P; Kambugu A; Ratanshi RP
    BMJ Open; 2018 Feb; 8(2):e015490. PubMed ID: 29467129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
    Moodley T; Moodley D; Sebitloane M; Maharaj N; Sartorius B
    BMC Pregnancy Childbirth; 2016 Feb; 16():35. PubMed ID: 26867536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
    J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia.
    Ayele G; Tessema B; Amsalu A; Ferede G; Yismaw G
    BMC Immunol; 2018 Dec; 19(1):37. PubMed ID: 30558580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine
    Sorsa A
    Open Med Inform J; 2018; 12():11-18. PubMed ID: 29875890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
    Shet A; Kumarasamy N; Poongulali S; Shastri S; Kumar DS; Rewari BB; Arumugam K; Antony J; De Costa A; D'Souza G
    Curr HIV Res; 2016; 14(1):71-9. PubMed ID: 26303008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
    Dokekias AE; Galiba FO; Bokilo AD; Ntsimba P; Nsitou MB; Malanda F; Basseila GB
    Bull Soc Pathol Exot; 2008 Apr; 101(2):109-12. PubMed ID: 18543703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Castelnuovo B; Kiragga A; Kamya MR; Manabe Y
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):59-63. PubMed ID: 20861741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
    Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study.
    Bokore A; Korme B; Bayisa G
    BMC Pharmacol Toxicol; 2018 Jun; 19(1):28. PubMed ID: 29871665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virologic Response Following a Switch to Dolutegravir-based Regimen in People Living with HIV/AIDS at a Tertiary Care Center in Nepal.
    Tamrakar R; Tamrakar D
    Kathmandu Univ Med J (KUMJ); 2022; 20(80):438-442. PubMed ID: 37795720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.